PIMASERTIB AND SEROUS RETINAL DETACHMENTS.
Alaa AlAli1, Ahmad Bushehri, Jonathan C Park
1Departments of *Ophthalmology and Vision Sciences, and †Radiation Oncology, University of Toronto, Toronto, Ontario, Canada.
Retinal Cases & Brief Reports
|October 8, 2015
Summary
Pimasertib, a MEK inhibitor, may cause multifocal serous retinal detachments. This visual toxicity resolved quickly after discontinuing the drug, highlighting a potential side effect in cancer treatment.
Area of Science:
- Ophthalmology
- Oncology
- Pharmacology
Background:
- Pimasertib is a MEK inhibitor investigated for low-grade metastatic ovarian cancer.
- Visual toxicity is a known concern with some targeted cancer therapies.
- Serous retinal detachments can impact vision and require careful monitoring.
